In this period, 231 (43%) of patients did not receive any immunosuppressants, whilst 307 (57%) received IMM or biologic therapies with a median interval of 12 (0–45) months after cancer diagnosis: specifically, 112 (21%) anti-TNFα, 64 MTX (12%), 79 (15%) thiopurines, 48 (9%) VDZ, and 4 (1%) USK (excluded from the analysis due to the limited number of patients). Here, TNF is linked to cancer.